10-Q quarterly report · filed Nov 13, 2026

UTAH MEDICAL PRODUCTS INC (UTMD) Q3 2026 10-Q Quarterly Report

Short answer

UTAH MEDICAL PRODUCTS INC (UTMD) filed its Q3 2026 10-Q quarterly report on Nov 13, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $9M (down 12.1% year over year) with net income of $3M.

Q3 2026 key financials · XBRL

Revenue
$9M
−12.1% YoY · +1.1% QoQ
Net income
$3M
+5.9% YoY · +3.8% QoQ
Operating margin
32.4%
Gross margin
56.1%
EPS (diluted)
$0.88
+7.3% YoY · +4.8% QoQ

Source: XBRL data from the UTAH MEDICAL PRODUCTS INC (UTMD) Q3 2026 10-Q on SEC EDGAR. USD.

UTAH MEDICAL PRODUCTS INC Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • 3Q revenue $8.621M, down 12.1% YoY from $9.812M, primarily lost PendoTECH and China distributor sales
  • Operating margin 32.4% vs 26.6% YoY, gross margin 56.1% vs 57.1%
  • Best category Blood Pressure Monitoring and Accessories $1.927M, up from $1.643M; worst Neonatal $1.667M, down from $2.176M
  • Cash and investments $85.2M vs $85.8M year-end, with $3.0M dividends, $0.9M repurchases and $5.0M Orion acquisition
  • 2026 revenue outlook down 7%-8%, EPS near $3.60 vs $3.48, with slower biopharma replacement sales and Filshie declines as headwinds

Risk Factors

  • No material changes disclosed from the December 31, 2025 Form 10-K risk factors
  • Unknown or currently immaterial risks could materially adversely affect business, financial condition, or operating results

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other UTAH MEDICAL PRODUCTS INC quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.